Vimarsana
Biggest News Aggregation in the World

Page 4 - Admission Document News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Admission Document. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Admission Document Today - Breaking & Trending Today

Creactives S p A : Group announces release of lock-up on 15.000 shares and simultaneous takeover of commitments by the new buyer -December 27, 2023 at 04:10 pm EST - Vimarsana News

Creactives S p A : Group announces release of lock-up on 15.000 shares and simultaneous takeover of commitments by the new buyer -December 27, 2023 at 04:10 pm EST

Creactives Group announces release of lock-up on 15.000 shares and simultaneous takeover of commitments by the new buyer Dec 27, 2023| Other price sensitive...

Investment Evolution Credit PLC Announces Admission to Trading and ... - Vimarsana News

Investment Evolution Credit PLC Announces Admission to Trading and ...

Investment Evolution Credit PLC Announces Admission to Trading and ...

Investegate | Company Announcement - Vimarsana News

Investegate | Company Announcement

Investegate announcements from Availability of Annual Report 2022 & AGM notice

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results - Vimarsana News

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

LONDON--(BUSINESS WIRE)--Nov 14, 2023--

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease - Vimarsana News

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Zerlasiran showed very significant and durable reductions in lipoprotein of up to 99% Lp levels remained around 90% lower than baseline at study endpoint ...